Celgene to Present Data From Abraxane Melanoma Study

Results from a late-stage clinical trial by Celgene Corp. show its cancer drug Abraxane slows the progression of melanoma. The trial compared Abraxane and dacarbazine in 529 patients with melanoma that had metastasized. The company says that patients treated with Abraxane had greater progression-free survival than patients treated with the dacarbazine. Celgene plans to present data from the study in November. Abraxane is currently approved as a treatment for breast cancer. The US Food and Drug Administration is scheduled to make a decision on Abraxane as a treatment for lung cancer later this year, and Celgene will also report data from a study of the drug as a treatment for pancreatic cancer.